Role of genetic and epigenetic changes in Burkitt lymphoma

Seminars in Cancer Biology

Volumn 12, Issue 5, 2002, Pages 381-387

  Lindström, Mikael S ^a   Wiman, Klas G ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

Author keywords

Burkitt lymphoma; c myc; Epstein Barr virus; Methylation; p16; p53

Indexed keywords

CYCLIN D; CYCLIN E; MYC PROTEIN; PROTEIN BAX; PROTEIN BCL 6; PROTEIN MDM2; PROTEIN P53; PROTEIN P73; RETINOBLASTOMA PROTEIN; TRANSCRIPTION FACTOR;

APOPTOSIS; ARTICLE; BURKITT LYMPHOMA; CELL CYCLE; EPSTEIN BARR VIRUS; GENE ACTIVATION; GENE AMPLIFICATION; GENE DELETION; GENE DISRUPTION; GENE EXPRESSION; GENE INACTIVATION; GENETICS; HUMAN; METHYLATION; NONHUMAN; PLASMACYTOMA; POINT MUTATION; PROMOTER REGION; TUMOR SUPPRESSOR GENE;

EID: 0036392058     PISSN: 1044579X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1044-579X(02)00058-5     Document Type: Article

References (67)

1. Hecht JL, Aster JC (2000) Molecular biology of Burkitt's lymphoma. J Clin Oncol 18:3707-3721
2. Klein G (1983) Specific chromosomal translocations and the genesis of B-cell-derived tumors in mice and men. Cell 32:311-315
3. Henriksson M, Selivanova G, Lindstrom M, Wiman KG (2001) Inactivation of Myc-induced p53-dependent apoptosis in human tumors. Apoptosis 6:133-137
4. McMahon SB, Wood MA, Cole MD (2000) The essential cofactor TRRAP recruits the histone acetyltransferase hGCN5 to c-Myc. Mol Cell Biol 20:556-562
5. Park J, Kunjibettu S, McMahon SB, Cole MD (2001) The ATM-related domain of TRRAP is required for histone acetyltransferase recruitment and Myc-dependent oncogenesis. Genes Dev 15:1619-1624
6. Lang SE, McMahon SB, Cole MD, Hearing P (2001) E2F transcriptional activation requires TRRAP and GCN5 cofactors. J Biol Chem 276:32627-32634
7. Gregory MA, Hann SR (2000) c-Myc proteolysis by the ubiquitin-proteasome pathway: stabilization of c-Myc in Burkitt's lymphoma cells. Mol Cell Biol 20:2423-2435
8. Bahram F, von der Lehr N, Cetinkaya C, Larsson LG (2000) c-Myc hot spot mutations in lymphomas result in inefficient ubiquitination and decreased proteasome-mediated turnover. Blood 95:2104-2110
9. Coller HA, Grandori C, Tamayo P, Colbert T, Lander ES, Eisenman RN, Golub TR (2000) Expression analysis with oligonucleotide microarrays reveals that MYC regulates genes involved in growth, cell cycle, signaling, and adhesion. Proc Natl Acad Sci USA 97:3260-3265
10. Santoni-Rugiu E, Falck J, Mailand N, Bartek J, Lukas J (2000) Involvement of Myc activity in a G(1)/S-promoting mechanism parallel to the pRb/E2F pathway. Mol Cell Biol 20:3497-3509
11. Gartel AL, Ye X, Goufman E, Shianov P, Hay N, Najmabadi F, Tyner AL (2001) Myc represses the p21(WAF1/CIP1) promoter and interacts with Sp1/Sp3. Proc Natl Acad Sci USA 98:4510-4515
12. Yang W, Shen J, Wu M, Arsura M, FitzGerald M, Suldan Z, Kim DW, Hofmann CS, Pianetti S, Romieu-Mourez R, Freedman LP, Sonenshein GE (2001) Repression of transcription of the p27(Kip1) cyclin-dependent kinase inhibitor gene by c-Myc. Oncogene 20:1688-1702
13. Wang J, Xie LY, Allan S, Beach D, Hannon GJ (1998) Myc activates telomerase. Genes Dev 12:1769-1774
14. Asker C, Wiman KG, Selivanova G (1999) p53-induced apoptosis as a safeguard against cancer. Biochem Biophys Res Commun 265:1-6
15. Sherr CJ (1998) Tumor surveillance via the ARF-p53 pathway. Genes Dev 12:2984-2991
16. Ko LJ, Prives C (1996) p53: puzzle and paradigm. Genes Dev 10:1054-1072
17. Bhatia KG, Gutierrez MI, Huppi K, Siwarski D, Magrath IT (1992) The pattern of p53 mutations in Burkitt's lymphoma differs from that of solid tumors. Cancer Res 52:4273-4276
18. Capoulade C, Bressac-de Paillerets B, Lefrere I, Ronsin M, Feunteun J, Tursz T, Wiels J (1998) Overexpression of MDM2, due to enhanced translation, results in inactivation of wild-type p53 in Burkitt's lymphoma cells. Oncogene 16:1603-1610
19. Cherney BW, Bhatia KG, Sgadari C, Gutierrez MI, Mostowski H, Pike SE, Gupta G, Magrath IT, Tosato G (1997) Role of the p53 tumor suppressor gene in the tumorigenicity of Burkitt's lymphoma cells. Cancer Res 57:2508-2515
20. Farrell PJ, Allan GJ, Shanahan F, Vousden KH, Crook T (1991) p53 is frequently mutated in Burkitt's lymphoma cell lines. EMBO J 10:2879-2887
21. Wiman KG, Magnusson KP, Ramqvist T, Klein G (1991) Mutant p53 detected in a majority of Burkitt lymphoma cell lines by monoclonal antibody PAb240. Oncogene 6:1633-1639
22. Vousden KH, Crook T, Farrell PJ (1993) Biological activities of p53 mutants in Burkitt's lymphoma cells. J Gen Virol 74:803-810
23. Tao W, Levine AJ (1999) Nucleocytoplasmic shuttling of onco-protein Hdm2 is required for Hdm2-mediated degradation of p53. Proc Natl Acad Sci USA 96:3077-3080
24. Hermeking H, Eick D (1994) Mediation of c-Myc-induced apoptosis by p53. Science 265:2091-2093
25. Sherr CJ (2001) The INK4a/ARF network in tumor suppression. Nat Rev Mol Cell Biol 2:731-737
26. Lindstrom MS, Klangby U, Inoue R, Pisa P, Wiman KG, Asker CE (2000) Immunolocalization of human p14(ARF) to the granular component of the interphase nucleolus. Exp Cell Res 256:400-410
27. Klangby U, Okan I, Magnusson KP, Wendland M, Lind P, Wiman KG (1998) p16/INK4a and p15/INK4b gene methylation and absence of p16/INK4a mRNA and protein expression in Burkitt's lymphoma. Blood 91:1680-1687
28. Baur AS, Shaw P, Burri N, Delacretaz F, Bosman FT, Chaubert P (1999) Frequent methylation silencing of p15(INK4b) (MTS2) and p16(INK4a) (MTS1) in B-cell and T-cell lymphomas. Blood 94:1773-1781
29. Sanchez-Beato M, Saez AI, Navas IC, Algara P, Sol Mateo M, Villuendas R, Camacho F, Sanchez-Aguilera A, Sanchez E, Piris MA (2001) Overall survival in aggressive B-cell lymphomas is dependent on the accumulation of alterations in p53, p16, and p27. Am J Pathol 159:205-213
30. Lindstrom MS, Klangby U, Wiman KG (2001) p14ARF homozygous deletion or MDM2 overexpression in Burkitt lymphoma lines carrying wild type p53. Oncogene 20:2171-2177
31. Pinyol M, Hernandez L, Martinez A, Cobo F, Hernandez S, Bea S, Lopez-Guillermo A, Nayach I, Palacin A, Nadal A, Fernandez PL, Montserrat E, Cardesa A, Campo E (2000) INK4a/ARF locus alterations in human non-Hodgkin's lymphomas mainly occur in tumors with wild-type p53 gene. Am J Pathol 156:1987-1996
32. Jacobs JJ, Scheijen B, Voncken JW, Kieboom K, Berns A, van Lohuizen M (1999) Bmi-1 collaborates with c-Myc in tumori-genesis by inhibiting c-Myc-induced apoptosis via INK4a/ARF. Genes Dev 13:2678-2690
33. Maestro R, Dei Tos AP, Hamamori Y, Krasnokutsky S, Sartorelli V, Kedes L, Doglioni C, Beach DH, Hannon GJ (1999) Twist is a potential oncogene that inhibits apoptosis. Genes Dev 13:2207-2217
34. van Kemenade FJ, Raaphorst FM, Blokzijl T, Fieret E, Hamer KM, Satijn DP, Otte AP, Meijer CJ (2001) Coexpression of BMI-1 and EZH2 polycomb-group proteins is associated with cycling cells and degree of malignancy in B-cell non-Hodgkin lymphoma. Blood 97:3896-3901
35. Bea S, Tort F, Pinyol M, Puig X, Hernandez L, Hernandez S, Fernandez PL, van Lohuizen M, Colomer D, Campo E (2001) BMI-1 gene amplification and overexpression in hematological malignancies occur mainly in mantle cell lymphomas. Cancer Res 61:2409-2412
36. Esteller M, Tortola S, Toyota M, Capella G, Peinado MA, Baylin SB, Herman JG (2000) Hypermethylation-associated inactivation of p14(ARF) is independent of p16(INK4a) methylation and p53 mutational status. Cancer Res 60:129-133
37. Gutierrez MI, Bhatia K, Siwarski D, Wolff L, Magrath IT, Mushinski JF, Huppi K (1992) Infrequent p53 mutation in mouse tumors with deregulated myc. Cancer Res 52:1032-1035
38. Zhang S, Ramsay ES, Mock BA (1998) Cdkn2a, the cyclin-dependent kinase inhibitor encoding p16INK4a and p19ARF, is a candidate for the plasmacytoma susceptibility locus, Pctr1. Proc Natl Acad Sci USA 95:2429-2434
39. Zhang SL, DuBois W, Ramsay ES, Bliskovski V, Morse III HC, Taddesse-Heath L, Vass WC, DePinho RA, Mock BA (2001) Efficiency alleles of the Pctr1 modifier locus for plasmacytoma susceptibility. Mol Cell Biol 21:310-318
40. Zhang S, Mock BA (1999) The role of p16INK4a (Cdkn2a) in mouse plasma cell tumors. Curr Top Microbiol Immunol 246:363-367
41. Adams JM, Harris AW, Pinkert CA, Corcoran LM, Alexander WS, Cory S, Palmiter RD, Brinster RL (1985) The c-myc oncogene driven by immunoglobulin enhancers induces lymphoid malignancy in transgenic mice. Nature 318:533-538
42. Eischen CM, Weber JD, Roussel MF, Sherr CJ, Cleveland JL (1999) Disruption of the ARF-Mdm2-p53 tumor suppressor pathway in Myc-induced lymphomagenesis. Genes Dev 13:2658-2669
43. Schmitt CA, McCurrach ME, de Stanchina E, Wallace-Brodeur RR, Lowe SW (1999) INK4a/ARF mutations accelerate lymphomagenesis and promote chemoresistance by disabling p53. Genes Dev 13:2670-2677
44. Inoue K, Roussel MF, Sherr CJ (1999) Induction of ARF tumor suppressor gene expression and cell cycle arrest by transcription factor DMP1. Proc Natl Acad Sci USA 96:3993-3998
45. Inoue K, Zindy F, Randle DH, Rehg JE, Sherr CJ (2001) Dmp1 is haplo-insufficient for tumor suppression and modifies the frequencies of Arf and p53 mutations in Myc-induced lymphomas. Genes Dev 15:2934-2939
46. Jacobs JJ, Kieboom K, Marino S, DePinho RA, van Lohuizen M (1999) The oncogene and Polycomb-group gene bmi-1 regulates cell proliferation and senescence through the ink4a locus. Nature 397:164-168
47. Kovalchuk AL, Qi CF, Torrey TA, Taddesse-Heath L, Feigenbaum L, Park SS, Gerbitz A, Klobeck G, Hoertnagel K, Polack A, Bornkamm GW, Janz S, Morse III HC (2000) Burkitt lymphoma in the mouse. J Exp Med 192:1183-1190
48. Gutierrez MI, Cherney B, Hussain A, Mostowski H, Tosato G, Magrath I, Bhatia K (1999) Bax is frequently compromised in Burkitt's lymphomas with irreversible resistance to Fas-induced apoptosis. Cancer Res 59:696-703
49. Brimmell M, Mendiola R, Mangion J, Packham G (1998) BAX frameshift mutations in cell lines derived from human haemopoietic malignancies are associated with resistance to apoptosis and microsatellite instability. Oncogene 16:1803-1812
50. Eischen CM, Roussel MF, Korsmeyer SJ, Cleveland JL (2001) Bax loss impairs Myc-induced apoptosis and circumvents the selection of p53 mutations during Myc-mediated lymphomagenesis. Mol Cell Biol 21:7653-7662
51. Raveh T, Kimchi A (2001) DAP kinase-a proapoptotic gene that functions as a tumor suppressor. Exp Cell Res 264:185-192
52. Raveh T, Droguett G, Horwitz MS, DePinho RA, Kimchi A (2001) DAP kinase activates a p19ARF/p53-mediated apoptotic checkpoint to suppress oncogenic transformation. Nat Cell Biol 3:1-7
53. Katzenellenbogen RA, Baylin SB, Herman JG (1999) Hypermethylation of the DAP-kinase CpG island is a common alteration in B-cell malignancies. Blood 93:4347-4353
54. Stiewe T, Putzer BM (2002) Role of p73 in malignancy: tumor suppressor or oncogene? Cell Death Differ 9:237-245
55. Corn PG, Kuerbitz SJ, van Noesel MM, Esteller M, Compitello N, Baylin SB, Herman JG (1999) Transcriptional silencing of the p73 gene in acute lymphoblastic leukemia and Burkitt's lymphoma is associated with 5′ CpG island methylation. Cancer Res 59:3352-3356
56. Irwin M, Marin MC, Phillips AC, Seelan RS, Smith DI, Liu W, Flores ER, Tsai KY, Jacks T, Vousden KH, Kaelin Jr WG (2000) Role for the p53 homologue p73 in E2F-1-induced apoptosis. Nature 407:645-648
57. Chang CC, Ye BH, Chaganti RS, Dalla-Favera R (1996) BCL-6, a POZ/zinc-finger protein, is a sequence-specific transcriptional repressor. Proc Natl Acad Sci USA 93:6947-6952
58. Ye BH, Lista F, Lo Coco F, Knowles DM, Offit K, Chaganti RS, Dalla-Favera R (1993) Alterations of a zinc finger-encoding gene, BCL-6, in diffuse large-cell lymphoma. Science 262:747-750
59. Capello D, Carbone A, Pastore C, Gloghini A, Saglio G, Gaidano G (1997) Point mutations of the BCL-6 gene in Burkitt's lymphoma. Br J Haematol 99:168-170
60. Capello D, Vitolo U, Pasqualucci L, Quattrone S, Migliaretti G, Fassone L, Ariatti C, Vivenza D, Gloghini A, Pastore C, Lanza C, Nomdedeu J, Botto B, Freilone R, Buonaiuto D, Zagonel V, Gallo E, Palestro G, Saglio G, Dalla-Favera R, Carbone A, Gaidano G (2000) Distribution and pattern of BCL-6 mutations throughout the spectrum of B-cell neoplasia. Blood 95:651-659
61. Shvarts A, Brummelkamp T, Scheeren F, Koh E, Daley GQ, Spits H, Bernards R (2002) A senescence rescue screen identifies BCL6 as an inhibitor of antiproliferative p19ARF-p53 signaling. Genes Dev 16:681-686
62. Sinclair AJ, Frost V (1999) Loss of functional pRB is not a ubiquitous feature of B-cell malignancies. Br J Cancer 80:670-675
63. Cinti C, Leoncini L, Nyongo A, Ferrari F, Lazzi S, Bellan C, Vatti R, Zamparelli A, Cevenini G, Tosi GM, Claudio PP, Maraldi NM, Tosi P, Giordano A (2000) Genetic alterations of the retinoblastoma-related gene RB2/p130 identify different pathogenetic mechanisms in and among Burkitt's lymphoma subtypes. Am J Pathol 156:751-760
64. Cinti C, Claudio PP, Howard CM, Neri LM, Fu Y, Leoncini L, Tosi GM, Maraldi NM, Giordano A (2000) Genetic alterations disrupting the nuclear localization of the retinoblastoma-related gene RB2/p130 in human tumor cell lines and primary tumors. Cancer Res 60:383-389
65. Klein G (2000) Dysregulation of lymphocyte proliferation by chromosomal translocations and sequential genetic changes. Bioassays 22:414-422
66. Takada K, Nanbo A (2001) The role of EBERs in oncogenesis. Semin Cancer Biol 11:461-467
67. Ruf IK, Rhyne PW, Yang C, Cleveland JL, Sample JT (2000) Epstein-Barr virus small RNAs potentiate tumorigenicity of Burkitt lymphoma cells independently of an effect on apoptosis. J Virol 74:10223-10228